tirzepatide – Medgate Today

Lilly’s tirzepatide superior to semaglutide in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

December 6, 2024

6:15 am

Participants using tirzepatide lost 22.8 kg and participants on semaglutide lost 15.0 kg SURMOUNT-5 compared tirzepatide, a dual GIP and GLP-1 receptor agonist, to semaglutide, a mono GLP-1 receptor agonist in adults living with obesity without diabetes Eli Lilly and Company (NYSE: LLY) today announced topline results

POST TAGS:

Ozempic reduces severity of liver disease in people with HIV, study shows

April 29, 2024

5:45 am

News Update

admin

A weekly injection of semaglutide was safe and reduced by 31% of liver fat in patients with HIV and liver disease-as per data from a mid-stage study presented by the National Institutes of Health showed. Data from the study was first released on Monday at the

POST TAGS:

Diabetes HIV injection liver National Institutes of Health Ozempic therapy tirzepatide

Lilly’s tirzepatide superior to semaglutide in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

POST TAGS:

Ozempic reduces severity of liver disease in people with HIV, study shows

POST TAGS:

FIND US

ADDRESS

FOLLOW US ON SOCIAL MEDIA